Background: All four dengue virus (DV) serotypes (D1V, D2V, D3V and D4V) can cause a series of disorders, ranging from mild dengue fever (DF) to severe dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS). Previous studies have revealed that DV serotype-specific CD8 + T cells are involved in controlling DV infection. Serotype cross-reactive CD8 + T-cells may contribute to the immunopathogenesis of DHF/DSS. The aim of the study was to identify HLA-A*0201-binding peptides from four DV serotypes. We then examined their immunogenicity in vivo and cross-reactivity within heterologous peptides. Methods: D1V-derived candidate CD8 + T-cell epitopes were synthesized and evaluated for their affinity to the HLA-A*0201 molecule. Variant peptides representing heterologous D2V, D3V, D4V serotypes were synthesized. The immunogenicity of the high-affinity peptides were evaluated in HLA-A*0201 transgenic mice. Results: Of the seven D1V-derived candidate epitopes [] also had a high affinity for HLA-A*0201 molecules. Furthermore, CD8 + T cells directed to these twelve peptides were induced in HLA-A*0201 transgenic mice following immunization with these peptides. Additionally, cross-reactivity within four peptides (D1V-NS4b [183][184][185][186][187][188][189][190][191] and D4V-NS4b 179-187 ) was observed.
Background
Dengue virus (DV) is a single-stranded positive-sense RNA virus, of which there are four serotypes (D1V, D2V, D3V and D4V). The viral genome encodes three structural proteins (C, M and E) and seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5). DV is known to cause a spectrum of illnesses, ranging from mild dengue fever (DF) to severe dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS). Currently, DF and DHF/DSS are major global public health problems. It is estimated that 50,000,000-100,000,000 cases of DF and 250,000-500,000 cases of DHF/DSS occur every year worldwide [1] .
Despite several decades of research, there are no effective and safe DV vaccines. Previous studies have shown that preexisting DV non-neutralizing antibodies can enhance secondary heterologous DV serotype infections via antibody-dependent enhancement (ADE). ADE may be the mechanism for development of DHF/DSS during secondary heterologous DV serotype infections [2] [3] [4] . It has been shown that infection with any one DV serotype provides the body with protective immunity against homologous DV serotypes, and with transient cross-protection against heterologous DV serotypes [5] .
The majority of studies have demonstrated that interferon gamma (IFN-γ) plays an important role in the clearance of DV following infection [6, 7] . Subsequent studies have indicated that DV-specific CD8 + T cells display lytic activity and/or produce IFN-γ [8, 9] . A recent study in mice confirmed that DV-specific CD8 + T cells play a crucial role in controlling DV replication and infection by secreting IFN-γ [10] . Thus, DV-specific CD8 + IFN-γ + T cells may be critical for controlling DV infection. However, growing evidence suggests that a DV serotype infection generates not only serotype-specific T cells, but also serotype cross-reactive T cells which can recognize multiple heterologous DV serotypes [9, [11] [12] [13] [14] [15] . At present, it is accepted that DV serotype-specific T cells provide protective immunity, while serotype crossreactive T cells induced by primary DV serotype infection are believed to mediate the immunopathogenesis of DHF/DSS during secondary heterologous DV serotype infection [8, [16] [17] [18] .
Because of the important role of serotype-specific CD8 + T cells in limiting DV infection, a new strategy for developing prophylactic and therapeutic CD8 + Tcell epitope-based vaccines is needed. To avoid the side effect of serotype cross-reactive CD8 + T cells, a dengue vaccine must be a tetravalent vaccine that is capable of providing protection against infection by all four DV serotypes simultaneously [19] . Tetravalent CD8 + T-cell epitope-based vaccines, which are mixtures of multiple heterologous variant CD8 + T-cell epitopes, could be promising candidate vaccines. Although many DV-specific CD8 + T-cell epitopes have been identified [9, 11, 12, 17, [20] [21] [22] [23] , the numbers of HLA-A*0201-restricted epitopes are limited, despite the high frequency of the HLA-A*0201 molecule in most populations.
In the present study, we sought to screen the amino acid sequences of D1V and used computational algorithms to predict potential HLA-A*0201-restricted CD8 + T-cell epitopes. Candidate CD8 + T-cell epitopes and their variant peptides in D2V, D3V, D4V were tested for their affinity to the HLA-A*0201 molecule, and for their capacity to induce CD8 + T-cell responses in HLA-A*0201 transgenic mice.
Results

Affinity of candidate CD8 + T-cell epitopes for HLA-A*0201
Seven D1V-derived candidate epitopes [D1V-NS4a 56-64 (MLLALIAVL), D1V-C 46-54 (LVMAFMAFL), D1V-NS4b 562-570 (LLATSIFKL), D1V-NS2a 169-177 (AMVLSIVSL), D1V-NS4a 140-148 (GLLFMILTV), D1V-NS2a 144-152 (QLWAALLSL) and D1V-NS4b 183-191 (LLMRTTWAL)] were synthesized. BLAST results showed that these peptides are highly conserved in more than 100 D1V strains (data not shown). MHC-peptide complex stabilization assay results indicated that three peptides (D1V-NS4a 140-148 , D1V-NS2a 144-152 and D1V-NS4b 183-191 ) showed peptide dose-dependent HLA-A*0201-peptide binding [fluorescence index (FI) exceeds 1 at a peptide concentration of 100 μg/ml], while the other peptides demonstrated weak binding to HLA-A*0201 (FI < 1; Table 1 and Figure 1 ). According to the sequences for D1V-NS4a 140-148 , D1V-NS2a 144-152 and D1V-NS4b [183] [184] [185] [186] [187] [188] [189] [190] [191] 
Induction of peptide-specific CD8 + T cells in HLA-A*0201 transgenic mice
To evaluate the immunogenicity of high-affinity peptides, splenocytes isolated from HLA-A*0201 transgenic mice immunized with peptide were stimulated with a cognate peptide. Enzyme-linked immunospot (ELISPOT) and intracellular cytokine staining (ICS) assays were used to detect homologous peptide-specific CD8 + T cells. ELI-SPOT results revealed that immunized HLA-A*0201 transgenic mice had high levels of peptide-specific IFN-γ spot-forming cells (SFCs) in splenocytes. All peptides evoked an IFN-γ response in the ELISPOT assay that exceeded 10 SFCs/1 × 10 5 splenocytes. D3V-NS2a 144-152 immunization resulted in the highest frequency of IFN-γsecreting cells (62 ± 9 SFCs/1 × 10 5 splenocytes), while D2V-NS4a 140-148 immunization showed the lowest frequency of IFN-γ-secreting cells (10 ± 3 SFCs/1 × 10 5 splenocytes). As for D1V-NS4a 140-148 and its variant peptides, with the increase of FI, higher level of peptide-specific IFN-γ-secreting cells was induced. In contrast, for D2V-NS2a 144-152 , D1V-NS4b 183-191 and their variant peptides, the frequencies of peptide-specific IFN-γ-secreting cells were not proportional to peptides' FIs. For example, the FIs of D1V-NS4a 140-148 and D3V-NS4a 140-148 were 4.5 and 4.05, respectively. These two peptides all induced higher level of IFN-γ-secreting cells (58 ± 8 SFCs and 37 ± 6 SFCs, respectively). Although D2V-NS2a 144-152 and D4V-NS4b 179-187 had higher FIs, they just induced median level of IFN-γ-secreting cells (21±3 SFCs and 22±4 SFCs, respectively). A summary of the individual peptides that evoked responses in IFN-γ ELISPOT assays is provided in Table 1 and Figures 2, 3, and 4. The ICS results defined the phenotype of peptide-specific IFN-γ-secreting T cells, and confirmed the human leukocyte antigen (HLA) restriction of these peptides. The high frequencies of CD8 + IFN-γ + T cells were detected in splenocytes after being stimulated with cognate peptide. The highest percentage of CD8 + IFN-γ + T cells was specific for D3V-NS2a 144-152 (0.79 ± 0.15%). The lowest percentage of CD8 + IFN-γ + T cells was directed against D2V-NS4a 140-148 (0.12 ± 0.05%; Table 1 , Figures 5, 6, and 7). The ELISPOT results were consistent with the ICS results. Additionally, these peptides were tested in an IFN-γ ELISPOT assay and an ICS assay using splenocytes from mock-immunized HLA-A*0201 transgenic mice. They were also tested using splenocytes from peptide-immunized C57BL/6 mice. Significant responses were not observed in either of these situations (data not shown).
Cross-reactivity of peptide-specific CD8 + T cells
To further explore the cross-reactivity between a given peptide and its variants, we examined the ability of peptide-specific CD8 + T cells to recognize a heterologous peptide variant representing another DV serotype. Splenocytes from D1V-NS4b 183-191 -immunized mice exhibited marked cross-reactivity towards D2V-NS4b 182- 
Discussion
Both our previous reports and other studies indicate that combining prediction algorithms with several in vitro and/or in vivo assays could hasten the identification of immunogenic T-cell epitopes [21, 24] . It is established that HLA-A*0201 is the major haplotype in most of the world population, irrespective of gender and race [25] . Therefore, HLA-A*0201-restricted CD8 + T-cell epitopes would likely have broad population coverage.
In the present study, seven D1V-derived potential HLA-A*0201-restricted candidate epitopes were evaluated for their binding capacity to HLA-A*0201. Three peptides were identified as high-affinity peptides. Almost all variants of these three peptides in D2V, D3V, D4V have a high affinity for HLA-A*0201. In total, twelve peptides demonstrated a high affinity for HLA-A*0201. Classic HLA-A*0201-restricted epitopes have an L or I amino acid residue at position 2, and an L, I or V residue at position 9. Among sixteen candidate epitopes described here, D1V-NS4a 140-148 , D3V-NS4a 140-148 , D4V-NS4a 140-148 , D1V-NS2a 144-152 , D2V-NS2a 144-152 , D3V-NS2a 144-152 , D1V-NS4b 183-191 and D3V-NS4b 182-190 followed this classic pattern. They also showed a high affinity for HLA-A*0201 (FI > 1). D1V-NS4a 56-64 and D1V-NS4b 562-570 had a lowaffinity for HLA-A*0201, even though they shared these classic residues at the relevant positions (FI < 0.5). In contrast, although neither D2V-NS4b 182-190 (position 2 is M) nor D4V-NS4b 179-187 (position 9 is F) conformed to the classic pattern, these peptides had a high affinity for HLA-A*0201 (FI > 4). A possible explanation for these phenomena may be that amino acids in other positions drastically affect binding avidity.
To further evaluate the immunogenicity and HLA allele restriction of these high-affinity peptides, we assessed whether these twelve peptides could elicit CD8 + T-cell responses in HLA-A*0201 transgenic mice. Although these twelve peptides had different affinities for HLA-A*0201, they all triggered peptide-specific CD8 + T cell responses. The magnitude of responses to individual peptides ranged from 10-62 SFCs/1×10 5 splenocytes. Our results appear to correspond with those seen in other studies. The frequencies of CD8 + IFN-γ + T cells that respond to cognate peptides in splenocytes of HLA-A*0201 transgenic mice (0.12-0.79% CD8 + IFN-γ + T cells of all CD3 + CD8 + T cells) is in line with frequencies detected in humanized mice (0.1-2.8% of all CD3 + CD8 + T cells) [26, 27] , and in human peripheral blood mononuclear cells (PBMCs) from DV immune donors (0.1-0.68% of all CD3 + CD8 + T cells) [12, 21] . These peptides did not induce significant CD8 + T-cell responses in mockimmunized HLA-A*0201 transgenic or C57BL/6 mice (data not shown). These data further confirmed that these twelve peptides were recognized by HLA-A*0201.
Additionally, a high frequency of D1V-NS4a 140-148 and D3V-NS2a 144-152 -specific CD8 + T cells in peptideimmunized HLA-A*0201 transgenic mice suggests that these peptides might be the immunodominant HLA-A*0201-restricted epitopes. In recent years, research studies have revealed many DV-specific CD8 + T-cell epitopes.
These are mostly located in E, NS3, NS4a, NS4b, NS5 and restricted by HLA-A2, A11, A24, B7, B55, B65 [9, 11, 12, 17, [20] [21] [22] [23] . Lund et al [22] and Weiskopf et al [23] used HLA-A*0201 transgenic mice and identified several D1V-and D2V-specific HLA-A*0201-retricted epitopes, respectively. Weiskopf et al [23] also found that most of the epitopes identified in the murine system are also recognized by PBMCs from DV-exposed human donors. In the present study, based on a similar strategy, we identified NS2a-, NS4a-and NS4b-derived HLA-A*0201restricted CD8 + T-cell epitopes from D1V-D4V. Our results suggest that NS2a, NS4a and NS4b are involved in cellular immunity during DV infection.
Previous studies have shown that DV-specific CD8 + T cells from DV-immunized or infected subjects exhibited a crossreactive response to variant peptides representing a heterologous serotype [9, 12, 15] . In this study, for D1V-NS4b 183-191 Figure 5 Detection of peptide-specific CD8 + IFN-γ + T cells in HLA-A*0201 transgenic mice immunized with D1V-NS4a 140-148 or heterologous peptides. Splenocytes were isolated from the peptide-immunized mice and were stimulated in vitro with cognate peptide or heterologous peptide. The percentages of CD8 + IFN-γ + T cells in CD8 + T cells were measured using ICS assay. *Indicating the positive response to a peptide. and its variant peptides (D2V-NS4b 182-190 , D3V-NS4b 182-190 and D4V-NS4b 179-187 ) each elicited peptide-specific CD8 + T cells, which exhibited cross-reactivity towards its variants. These data suggest that D1V infection followed by D2V, D3V or D4V infection (or vice versa) would trigger the activation of cross-reactive IFN-γ-producing CD8 + T cells. Cross-reactivity may be explained by the primary structure of these variants: D2V-NS4b 182-190 (LMMRTTWAL), D3V-NS4b 182-190 (LLMRTSWAL), and D4V-NS4b 179-187 (LLM RTTWAF). Each of these differs from D1V-NS4b [183] [184] [185] [186] [187] [188] [189] [190] [191] (LLMRTTWAL) by a single amino acid. D1V-NS4b 183-191 and D3V-NS4b 182-190 shared the same anchors at positions 2 (L) and 9 (L). These are critical positions for HLA recognition and T-cell activation. These two peptides have only one amino acid change at position 6 (T→S). For D2V-NS4b 182-190 and D4V-NS4b 179-187 , the residues at positions 2 or 9 differ from D1V-NS4b 183-191 and D3V-NS4b [182] [183] [184] [185] [186] [187] [188] [189] [190] . We believe that the amino acid change will not affect functional avidity (IFN-γ secretion). In a recent study using HLA-A*0201-positive D1V/D2V/D3V-immune donors, Bashyam et al [12] reported four cross-reactive epitopes (D1V-ILLMRTTWA, D2V-VLLMRTTWA, D3V-LLLMRTSWA and D4V-LLL MRTTWA). In comparison, we found those epitopes along with the ones reported in this paper to share 7 or 8 amino acids. We are confident that the shared amino acid sequences may determine HLA-A*0201 restriction and T cell recognition.
Conclusions
In summary, based on the amino acid sequences of D1V-D4V, we identified two novel serotype-specific HLA-A*0201- Figure 6 Detection of peptide-specific CD8 + IFN-γ + T cells in HLA-A*0201 transgenic mice immunized with D1V-NS2a 144-152 or heterologous peptides. Splenocytes were isolated from peptide-immunized mice and were stimulated in vitro with cognate peptide or heterologous peptide. The percentages of CD8 + IFN-γ + T cells in CD8 + T cells were measured using ICS assay. *Indicating the positive response to a peptide.
restricted CD8 + T-cell epitopes (NS4a 140-148 and NS2a 144-152 ) and one cross-reactive HLA-A*0201-restricted CD8 + T-cell epitopes which is similar to a previously identified epitope. In the following study, we would explore whether these peptide could be recognized by PBMCs from human donors infected with DV. Our results show that using a combination of prediction algorithms and HLA transgenic mice is effective for identifying HLArestricted epitopes. In general, the antiviral activity of CD8 + T cells is mediated by the production of cytokines, particularly IFN-γ. Further studies will be needed to determine the protective role of these serotype-specific epitopes. D1V-NS4b 183-191 , D2V-NS4b 182-190 , D3V-NS4b 182-190 and D4V-NS4b 179-187 cross-reacted with each other, therefore further evaluation of the functional phenotype of serotype cross-reactive CD8 + T cells induced by these peptides would reveal the exact mechanism of T cell-mediated immunopathogenesis during secondary heterologous DV serotype infection.
Methods
Epitope prediction and peptide synthesis
Based on the amino acid sequence of D1V (Hawaii strain; GenBank Accession No: ACF49259), the epitope prediction algorithms SYFPEITHI with PAProc (http://www.syfpeithi.de; http://www.paproc.de) were applied to predict HLA-A*0201-restricted CD8 + T-cell epitopes. The following criteria were used to select candidate CD8 + T-cell epitopes. First, the candidate epitope should be a nonapeptide that has a high predictive score and a protease cleavage site (C terminus). Second, the sequence of the candidate epitope should be highly conserved in most D1V strains. If a candidate epitope has a high affinity for HLA-A*0201 as confirmed by an MHC peptide complex stabilization assay, its variant peptides in D2V (NGC strain; AAC59275), D3V (H87 strain; AAA99437) and D4V (H241 strain; AAX48017) would be selected and synthesized. All peptides were synthesized at > 90% purity by ChinaPeptides Co., Ltd (Shanghai, China).
Cells and mice
The transporter associated with antigen processing (TAP)-deficient T2 cell line was purchased from ATCC (Manassas, VA, USA). Female C57BL/6-Transgenic (HLA-A2.1)1Enge/J mice (HLA-A*0201 transgenic mice; 6-8 weeks) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Female C57BL/6 mice (6-8 weeks) were provided by the Laboratory Animal Center of Wenzhou Medical College.
MHC-peptide complex stabilization assay
The ability of peptides to stabilize MHC molecules on the surface of T2 cells was measured as described previously [21] . T2 cells (2 × 10 5 cells/0.5 ml) were incubated in serum-free RPMI 1640 medium in the presence of different concentrations of peptide (1, 10, 100 μg/ml) for 1 h at 37°C/5% CO 2 incubator. Cells were then incubated at 26°C for 12 h, and then returned to 37°C for a 3 h incubation. Finally, T2 cells were stained with FITCconjugated anti-HLA-A*0201 antibody (BD Pharmingen, USA) for 40 min at 4°C. T2 cells incubated in serum-free RPMI 1640 medium without peptides served as a negative control (background). Mean fluorescence intensity (MFI) of T2 cells was recorded with a FACS Calibur flow cytometer (BD bioscience, USA), and results expressed as fluorescence index (FI). The following formula was used to calculate the FI.
FI ¼ MFI sample À MFI background MFI background
Immunization of HLA-A*0201 transgenic mice HLA-A*0201 transgenic mice were subdivided into 12 groups (4 mice/group). Mice were inoculated subcutaneously with high-affinity peptide (50 μg/mouse) emulsified in Freund's complete adjuvant. One week later, mice were immunized with the same peptide emulsified in Freund's incomplete adjuvant. Mice were boosted three more times at weekly intervals. Mock-immunized (adjuvant alone) HLA-A*0201 transgenic mice and peptide-immunized C57BL/6 mice served as controls. One week after the final immunization, all mice were sacrificed and splenocytes extracted. ELISPOT and ICS assays were conducted to detect the frequencies of peptide-specific IFN-γ-producing cells. All animal were performed following the Institutional Animal Care and Use Committee-approved protocols.
IFN-γ ELISPOT assays
Splenocytes were resuspended to a final concentration of 1 × 10 6 cells/ml in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). ELISPOT assays were performed in pre-coated 96-well plates (U-CyTech Company, Netherlands). Splenocytes were seeded at 1 × 10 5 cells/well and exposed to either cognate or heterologous peptide at a final concentration of 10 μg/ml. Negative control wells contained splenocytes but no peptide. Positive control wells included cells plus phytohemagglutinin (PHA) at a final concentration of 10 μg/ml. All tests were carried out in duplicate wells, with plates incubated for 24 h at 37°C/5% CO 2 . Plates were washed and then incubated with biotinylated anti-mouse IFN-γ for 1 h at 37°C. After washing, plates were labeled with streptavidinhorseradish peroxidase, and developed using fresh ACE solution as a substrate. IFN-γ spots were counted using an ELISPOT reader (Beijing SageCreation Science Co. Ltd, Beijing, China). Peptide-specific T-cell frequency was expressed as SFCs/1 × 10 5 splenocytes. Background spots (negative control wells) were subtracted from test wells. A positive response to a peptide was defined as having > 5 SFCs/1 × 10 5 splenocytes after subtraction of the background.
ICS assays
Splenocytes were cultured with either cognate peptide (10 μg/ml) or heterologous peptide (10 μg/ml) in a 1.5 ml microcentrifuge tube for 6 h at 37°C/5% CO 2 . Negative controls did not receive any peptide stimulation. During the last 5 h, brefeldin A (10 μg/ml) was added to each tube. After a 6 h incubation, cells were washed and then stained with APC-conjugated anti-mouse CD3 and FITCconjugated anti-mouse CD8 antibodies (eBioscience company, USA) for 40 min at 4°C. Cells were then washed and fixed with 4% paraformaldehyde for 20 min at 4°C, permeabilized using 0.5% saponin for 10 min at 4ºC, and stained with PE-conjugated anti-mouse IFN-γ antibody (eBioscience company, USA) for 40 min at 4°C. A FACS Calibur flow cytometer (BD Bioscience, USA) was used to analyze labeled cells. CD3 + CD8 + T cells were gated and the proportion of IFN-γ-producing CD8 + T cells (CD8 + IFN-γ + T cells) as a subset of all CD8 + T cells were determined.
Statistical analysis
